These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27819149)

  • 61. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Antman EM; Braunwald E; Giugliano RP
    Thromb Haemost; 2021 Feb; 121(2):140-149. PubMed ID: 32920808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Establishing Edoxaban's Role in Anticoagulation.
    Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
    J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
    Ameri P; Riva L; Toma M; Di Pasquale G; De Caterina R
    G Ital Cardiol (Rome); 2020 Jul; 21(7):546-557. PubMed ID: 32555574
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
    Ahrens I; Bode C
    Hamostaseologie; 2012; 32(3):212-5. PubMed ID: 22786687
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
    Masjuan J; DeFelipe A
    Int J Neurosci; 2017 Aug; 127(8):716-725. PubMed ID: 27586690
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
    Song S; Kang D; Halim AB; Miller R
    J Clin Pharmacol; 2014 Aug; 54(8):910-6. PubMed ID: 24706516
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
    Partida RA; Giugliano RP
    Future Cardiol; 2011 Jul; 7(4):459-70. PubMed ID: 21797743
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
    AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
    Cohen AA; Heidbuchel H; Le Heuzey JY; De Caterina R; Merino JL; Jin J; Melino M; Winters SM; Goette A; Lip GYH
    Am Heart J; 2019 Mar; 209():131-135. PubMed ID: 30635112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.